PURPOSE: Local failure in unresectable pancreatic cancer may contribute to death. We hypothesized that intensification of local therapy would improve local control and survival. The objectives were to determine the maximum tolerated radiation dose delivered by intensity modulated radiation with fixed-dose rate gemcitabine (FDR-G), freedom from local progression (FFLP), and overall survival (OS). METHODS AND MATERIALS: Eligibility included pathologic confirmation of adenocarcinoma, radiographically unresectable, performance status of 0-2, absolute neutrophil count of ≥ 1,500/mm(3), platelets ≥ 100,000/mm(3), creatinine <2 mg/dL, bilirubin <3 mg/dL, and alanine aminotransferase/aspartate aminotransferase ≤ 2.5 × upper limit of normal. FDR-G (1000 mg/m(2)/100 min intravenously) was given on days -22 and -15, 1, 8, 22, and 29. Intensity modulated radiation started on day 1. Dose levels were escalated from 50-60 Gy in 25 fractions. Dose-limiting toxicity was defined as gastrointestinal toxicity grade (G) ≥ 3, neutropenic fever, or deterioration in performance status to ≥ 3 between day 1 and 126. Dose level was assigned using TITE-CRM (Time-to-Event Continual Reassessment Method) with the target dose-limiting toxicity (DLT) rate set to 0.25. RESULTS: Fifty patients were accrued. DLTs were observed in 11 patients: G3/4 anorexia, nausea, vomiting, and/or dehydration (7); duodenal bleed (3); duodenal perforation (1). The recommended dose is 55 Gy, producing a probability of DLT of 0.24. The 2-year FFLP is 59% (95% confidence interval [CI]: 32-79). Median and 2-year overall survival are 14.8 months (95% CI: 12.6-22.2) and 30% (95% CI 17-45). Twelve patients underwent resection (10 R0, 2 R1) and survived a median of 32 months. CONCLUSIONS: High-dose radiation therapy with concurrent FDR-G can be delivered safely. The encouraging efficacy data suggest that outcome may be improved in unresectable patients through intensification of local therapy.
PURPOSE:Local failure in unresectable pancreatic cancer may contribute to death. We hypothesized that intensification of local therapy would improve local control and survival. The objectives were to determine the maximum tolerated radiation dose delivered by intensity modulated radiation with fixed-dose rate gemcitabine (FDR-G), freedom from local progression (FFLP), and overall survival (OS). METHODS AND MATERIALS: Eligibility included pathologic confirmation of adenocarcinoma, radiographically unresectable, performance status of 0-2, absolute neutrophil count of ≥ 1,500/mm(3), platelets ≥ 100,000/mm(3), creatinine <2 mg/dL, bilirubin <3 mg/dL, and alanine aminotransferase/aspartate aminotransferase ≤ 2.5 × upper limit of normal. FDR-G (1000 mg/m(2)/100 min intravenously) was given on days -22 and -15, 1, 8, 22, and 29. Intensity modulated radiation started on day 1. Dose levels were escalated from 50-60 Gy in 25 fractions. Dose-limiting toxicity was defined as gastrointestinal toxicity grade (G) ≥ 3, neutropenic fever, or deterioration in performance status to ≥ 3 between day 1 and 126. Dose level was assigned using TITE-CRM (Time-to-Event Continual Reassessment Method) with the target dose-limiting toxicity (DLT) rate set to 0.25. RESULTS: Fifty patients were accrued. DLTs were observed in 11 patients: G3/4 anorexia, nausea, vomiting, and/or dehydration (7); duodenal bleed (3); duodenal perforation (1). The recommended dose is 55 Gy, producing a probability of DLT of 0.24. The 2-year FFLP is 59% (95% confidence interval [CI]: 32-79). Median and 2-year overall survival are 14.8 months (95% CI: 12.6-22.2) and 30% (95% CI 17-45). Twelve patients underwent resection (10 R0, 2 R1) and survived a median of 32 months. CONCLUSIONS: High-dose radiation therapy with concurrent FDR-G can be delivered safely. The encouraging efficacy data suggest that outcome may be improved in unresectable patients through intensification of local therapy.
Authors: R A Wolff; D B Evans; D M Gravel; R Lenzi; P W Pisters; J E Lee; N A Janjan; C Charnsangavej; J L Abbruzzese Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: H M Ceha; G van Tienhoven; D J Gouma; C H Veenhof; C J Schneider; E A Rauws; S S Phoa; D González González Journal: Cancer Date: 2000-12-01 Impact factor: 6.860
Authors: Aaron C Spalding; Kyung-Wook Jee; Karen Vineberg; Marla Jablonowski; Benedick A Fraass; Charlie C Pan; Theodore S Lawrence; Randall K Ten Haken; Edgar Ben-Josef Journal: Med Phys Date: 2007-02 Impact factor: 4.071
Authors: C J McGinn; M M Zalupski; I Shureiqi; J M Robertson; F E Eckhauser; D C Smith; D Brown; G Hejna; M Strawderman; D Normolle; T S Lawrence Journal: J Clin Oncol Date: 2001-11-15 Impact factor: 44.544
Authors: William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Christopher H Crane; Kathryn Winter; William F Regine; Howard Safran; Tyvin A Rich; Walter Curran; Robert A Wolff; Christopher G Willett Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Meredith Morgan; Mohamed A El Shaikh; Eyad Abu-Isa; Mary A Davis; Theodore S Lawrence Journal: Transl Oncol Date: 2008-03 Impact factor: 4.243
Authors: J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber Journal: J Clin Oncol Date: 1991-03 Impact factor: 44.544
Authors: Hanna K Sanoff; Allison M Deal; Janakiraman Krishnamurthy; Chad Torrice; Patrick Dillon; Jessica Sorrentino; Joseph G Ibrahim; Trevor A Jolly; Grant Williams; Lisa A Carey; Amy Drobish; Brittaney-Belle Gordon; Shani Alston; Arti Hurria; Karin Kleinhans; K Lenhard Rudolph; Norman E Sharpless; Hyman B Muss Journal: J Natl Cancer Inst Date: 2014-03-28 Impact factor: 13.506
Authors: Carl G Engelke; Leslie A Parsels; Yushen Qian; Qiang Zhang; David Karnak; Jordan R Robertson; Daria M Tanska; Dongping Wei; Mary A Davis; Joshua D Parsels; Lili Zhao; Joel K Greenson; Theodore S Lawrence; Jonathan Maybaum; Meredith A Morgan Journal: Clin Cancer Res Date: 2013-06-26 Impact factor: 12.531
Authors: David Karnak; Carl G Engelke; Leslie A Parsels; Tasneem Kausar; Dongping Wei; Jordan R Robertson; Katherine B Marsh; Mary A Davis; Lili Zhao; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan Journal: Clin Cancer Res Date: 2014-08-12 Impact factor: 12.531
Authors: Agata I Rembielak; Pooja Jain; Andrew S Jackson; Melanie M Green; Gillian R Santorelli; Gillian A Whitfield; Adrian Crellin; Angel Garcia-Alonso; Ganesh Radhakrishna; James Cullen; M Ben Taylor; Ric Swindell; Catharine M West; Juan Valle; Azeem Saleem; Patricia M Price Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243
Authors: William A Hall; Lauren E Colbert; Dana Nickleach; Jeffrey Switchenko; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; Claire Hardy; David A Kooby; Roshan S Prabhu; John Kauh; Jerome C Landry Journal: J Gastrointest Oncol Date: 2014-04
Authors: Samhita Chakraborty; Monica M Morris; Todd W Bauer; Reid B Adams; Edward B Stelow; Gina Petroni; Hanna K Sanoff Journal: Gastrointest Cancer Res Date: 2014-01
Authors: Sunil Krishnan; Awalpreet S Chadha; Yelin Suh; Hsiang-Chun Chen; Arvind Rao; Prajnan Das; Bruce D Minsky; Usama Mahmood; Marc E Delclos; Gabriel O Sawakuchi; Sam Beddar; Matthew H Katz; Jason B Fleming; Milind M Javle; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-11 Impact factor: 7.038